Optimising Outcomes in Chronic Myeloid Leukaemia Through Rational Drug Selection Using Predictive Assay Results and Maximising Treatment Free Remissions

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1146253

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Although outcomes in chronic myeloid leukaemia are generally excellent, a number of important questions remain. In this grant, we propose to i) personalise the selection of frontline treatment for newly diagnosed patients, using biomarkers which can predict treatment response; ii) improve the probability of cure in patients aiming to stop their treatment, and iii) use ultra-sensitive molecular tests for disease detection to predict risk of disease relapse.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2021

Funding Scheme: Early Career Fellowships

Funding Amount: $193,596.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cancer Therapy (excl. Chemotherapy and Radiation Therapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

chronic myeloid leukaemia (CML) | clinical trial | leukaemia | minimal residual disease | side-effects

Related Links